By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Tricyclic antidepressant > Clomipramine

Clomipramine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|629 words

Clomipramine Drug Profile

What is Clomipramine?

Clomipramine is a tricyclic antidepressant (TCA) medication primarily used to treat obsessive-compulsive disorder and depression. It belongs to a class of older antidepressants that work by affecting neurotransmitter levels in the brain. Unlike other tricyclic antidepressants, clomipramine has particularly strong effects on serotonin reuptake, making it especially effective for obsessive-compulsive symptoms.

Uses

Clomipramine is prescribed for several psychiatric conditions:

  • Obsessive-Compulsive Disorder (OCD): The primary FDA-approved indication, clomipramine helps reduce repetitive thoughts and compulsive behaviors characteristic of OCD.
  • Major Depressive Disorder: Used to treat moderate to severe depression, particularly when other antidepressants have been ineffective.
  • Panic Disorder: May be prescribed off-label to help prevent panic attacks and reduce anticipatory anxiety.
  • Chronic Pain Conditions: Sometimes used off-label for neuropathic pain, fibromyalgia, and other chronic pain syndromes.
  • Body Dysmorphic Disorder: May be prescribed off-label for this condition that shares similarities with OCD.

How it works

Clomipramine works by blocking the reuptake of neurotransmitters, particularly serotonin and norepinephrine, in the brain. By preventing these chemical messengers from being reabsorbed too quickly, the medication increases their availability at nerve synapses. This enhanced neurotransmitter activity is believed to improve mood, reduce obsessive thoughts, and decrease compulsive behaviors over time.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Dry mouth
  • Constipation
  • Drowsiness and fatigue
  • Dizziness
  • Weight gain
  • Sexual dysfunction
  • Sweating
  • Blurred vision

Serious side effects that require immediate medical attention:

  • Suicidal thoughts or behaviors, especially in young adults
  • Severe allergic reactions with rash, swelling, or difficulty breathing
  • Heart rhythm abnormalities or chest pain
  • Seizures
  • Severe confusion or hallucinations

Warnings and precautions

  • Suicide Risk: Clomipramine carries a black box warning for increased suicide risk in children, adolescents, and young adults under 25, particularly during the first few months of treatment.
  • Pregnancy and Breastfeeding: Classified as pregnancy category C; should only be used if potential benefits outweigh risks. The medication passes into breast milk and may affect nursing infants.
  • Heart Conditions: Should be used with extreme caution in patients with heart disease, as tricyclic antidepressants can affect heart rhythm and blood pressure.
  • Elderly Patients: Older adults are more susceptible to side effects, particularly falls due to dizziness and confusion.
  • Liver and Kidney Function: Dosage adjustments may be necessary in patients with liver or kidney impairment, as the medication is metabolized by the liver and excreted by the kidneys.

Interactions

  • MAO Inhibitors: Dangerous, potentially fatal interaction; must wait at least 14 days between stopping MAOIs and starting clomipramine.
  • SSRIs and SNRIs: Increased risk of serotonin syndrome when combined with other serotonergic medications.
  • Blood Thinners: Clomipramine may increase bleeding risk when used with warfarin or other anticoagulants.
  • Heart Medications: Can interact with antiarrhythmic drugs and increase risk of heart rhythm problems.
  • Sedatives: Enhanced drowsiness when combined with alcohol, benzodiazepines, or sleep medications.
  • Cimetidine: This stomach acid reducer can increase clomipramine levels in the blood.
  • St. John’s Wort: This herbal supplement may reduce clomipramine effectiveness and increase side effects.
  • Tramadol: Increased risk of seizures when used together.

Check interactions with the GMJ Interaction Checker

Dosage

Dosage varies significantly based on the condition being treated and individual patient response. For adults with OCD, treatment typically begins with 25mg daily, gradually increased over several weeks to a usual maintenance dose of 100-250mg daily. Depression treatment often starts with 25mg daily, with gradual increases to 100-150mg daily as needed. Maximum daily doses generally should not exceed 250mg. Elderly patients typically require lower doses due to increased sensitivity to side effects. All dosage adjustments should be made slowly under medical supervision, and patients should never stop taking clomipramine abruptly due to risk of withdrawal symptoms.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Clomipramine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/clomipramine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Health Security Agency Launches Evidence-Based Training Programme for Healthcare Staff

The UK Health Security Agency has launched a structured training programme to…

Two Words, One Sector: Why STAT News Keeps ‘Health Care’ Separate

STAT News formalizes editorial convention to maintain 'health care' as two words,…

Tracing transgender identity through history: Evidence from ancient civilizations to modern terminology

Historical records from ancient Egypt, Mesopotamia, Greece, and Rome document individuals who…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Nortriptyline

By
Prof. Giorgi Pkhakadze
02/06/2026

Imipramine

By
Prof. Giorgi Pkhakadze
02/06/2026

Desipramine

By
Prof. Giorgi Pkhakadze
02/06/2026

Doxepin

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up